Why the study?
The use of biomarkers in cardiorenal syndrome is still in its infancy, and further research is needed to establish their utility in routine clinical practice.
What is the role of biomarkers in the diagnosis, prognosis, and management of cardiorenal syndrome?
What is the role of biomarkers in the diagnosis, prognosis, and management of cardiorenal syndrome?
Emerging and established biomarkers offer potential for early detection and personalized management of cardiorenal syndrome, though further research is needed to establish routine clinical utility.
May aid individualized CRS assessment; leaves open prospective validation before practice change.
Biomarkers have become important tools in the diagnosis and management of cardiorenal syndrome (CRS), a complex condition characterized by dysfunction in both the cardiovascular and renal systems. Biomarkers can help identify the presence and severity of CRS, predict its progression and outcomes, and facilitate personalized treatment options. Several biomarkers, including natriuretic peptides, troponins, and inflammatory markers, have been extensively studied in CRS, and have shown promising results in improving diagnosis and prognosis. In addition, emerging biomarkers, such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, offer potential for early detection and intervention of CRS. However, the use of biomarkers in CRS is still in its infancy, and further research is needed to establish their utility in routine clinical practice. This review highlights the role of biomarkers in the diagnosis, prognosis, and management of CRS, and discusses their potential as valuable clinical tools for personalized medicine in the future.
No takes yet. Share an insight, caveat, or question.
Granado et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: